← Back to Search

Behavioural Intervention

Exoskeleton-Assisted Movement for Stroke

N/A

Recruiting

Led By Jose L Pons, Ph.D

Research Sponsored by Shirley Ryan AbilityLab

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No history of a brain and/or skull lesion

Age from 18 to 80 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up for experiment b, change between baseline and through participant completion, an average of 3 months.

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether the decoder can control the exoskeleton in real-time based on HD-EMG recordings from the participant's muscles with the aim of providing functional assistance.

Who is the study for?

This trial is for adults aged 18-80 with normal movement in their limbs, no brain/skull lesions, correctable hearing and vision. It includes stroke survivors who had a unilateral, supratentorial stroke over 6 months ago without other neurological disorders.

What is being tested?

The study tests a new controller for exoskeletons that uses muscle signals to predict movements. Participants will perform various muscle contractions and activities while wearing an exoskeleton that's guided by this technology.

What are the potential side effects?

Since the intervention involves physical activity with an exoskeleton based on muscle signals, potential side effects may include muscle fatigue or discomfort from the device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have never had a brain or skull lesion.

Select...

I am between 18 and 80 years old.

Select...

My hearing and vision are normal or corrected to normal.

Select...

I do not have any conditions that cause unusual movements in my arms or legs.

Select...

I do not have any neurological disorders.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ for experiment b, change between baseline and through participant completion, an average of 3 months.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~for experiment b, change between baseline and through participant completion, an average of 3 months.

This trial's timeline: 3 weeks for screening, Varies for treatment, and for experiment b, change between baseline and through participant completion, an average of 3 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in 10WMT

Change in 6MWT

Change in Berg Balance Scale

+8 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Healthy ParticipantsExperimental Treatment5 Interventions

The investigators will look at muscle activity of healthy participants from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).

Group II: Clinical ParticipantsExperimental Treatment5 Interventions

The investigators will look at muscle activity of participants post-stroke from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).

0 / 5Eligibility criteria met